Mitostatin is down-regulated in human prostate cancer and suppresses the invasive phenotype of prostate cancer cells

MITOSTATIN, a novel putative tumor suppressor gene induced by decorin overexpression, is expressed in most normal human tissues but is markedly down-regulated in advanced stages of mammary and bladder carcinomas. Mitostatin negatively affects cell growth, induces cell death and regulates the express...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 6; no. 5; p. e19771
Main Authors Fassan, Matteo, D'Arca, Domenico, Letko, Juraj, Vecchione, Andrea, Gardiman, Marina P, McCue, Peter, Wildemore, Bernadette, Rugge, Massimo, Shupp-Byrne, Dolores, Gomella, Leonard G, Morrione, Andrea, Iozzo, Renato V, Baffa, Raffaele
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 06.05.2011
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:MITOSTATIN, a novel putative tumor suppressor gene induced by decorin overexpression, is expressed in most normal human tissues but is markedly down-regulated in advanced stages of mammary and bladder carcinomas. Mitostatin negatively affects cell growth, induces cell death and regulates the expression and activation levels of Hsp27. In this study, we demonstrated that ectopic expression of Mitostatin in PC3, DU145, and LNCaP prostate cancer cells not only induced a significant reduction in cell growth, but also inhibited migration and invasion. Moreover, Mitostatin inhibited colony formation in soft-agar of PC3 and LNCaP cells as well as tumorigenicity of LNCaP cells in nude mice. Conversely, targeting endogenous Mitostatin by siRNA and anti-sense strategies in PC3 and DU145 prostate cancer cells enhanced the malignant phenotype in both cell lines. In agreement of these anti-oncogenic roles, we discovered that Mitostatin was absent in ∼35% (n = 124) of prostate tumor samples and its overall reduction was associated with advanced cancer stages. Collectively, our findings indicate that MITOSTATIN may acts as a tumor suppressor gene in prostate cancer and provide a novel cellular and molecular mechanism to be further exploited and deciphered in our understanding of prostate cancer progression.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Conceived and designed the experiments: MF AM RVI RB. Performed the experiments: MF DD JL AV BW. Analyzed the data: MF DS-B LGG AM RVI RB. Contributed reagents/materials/analysis tools: MPG PM MR LGG AM RB. Wrote the paper: MF AM RB.
Current address: Global Oncology Division, Sanofi-Aventis, Cambridge, Massachusetts, United States of America
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0019771